Navigation Links
CryoCath Appoints Vice President, Europe
Date:7/2/2008 Toronto Stock Exchange Symbol: CYT

MONTREAL, July 2 /PRNewswire-FirstCall/ - CryoCath Technologies Inc. (TSX: CYT), the global leader in cryotherapy products to treat cardiac arrhythmias, today announced the appointment of Frank Vandeputte as Vice President, Europe. Based in CryoCath's new European headquarters in Leiden, The Netherlands, Mr. Vandeputte will be responsible for leading the European business operation. This includes the development and implementation of strategic and operational business plans, with the objective of driving ongoing rapid sales growth of the Company's innovative products in the European market.

Mr. Vandeputte joins CryoCath with more than 20 years of experience in the medical device industry. Most recently, he served as Area Vice President Benelux and Nordic for the Sorin Group, based in Brussels. Prior to that he was Vice President International Marketing with the Sorin Group. Prior to Sorin, he held senior management positions with leading medical device companies, including Baxter International Inc, Becton Dickinson and Guidant Corporation. With Guidant, he has been providing leadership to their European Cardiac Resynchronisation Therapy, Endovascular and Cardiac Surgery business, and served as Country Manager for Germany as well.

"With his proven leadership and medical device industry successes, Frank will be an asset to our European commercial operations. He, and his successful European leadership team, will spearhead the ongoing rapid growth of Arctic Front in Europe," said Jan Keltjens, CryoCath President and CEO. "Additionally, we have now opened our European headquarters in Leiden, the Netherlands. This will allow us to better serve the needs of our expanding customer base in Europe. By establishing a strong European presence and enhancing our management team, we are continuing to execute on our strategy of becoming a leader in atrial fibrillation therapy."

About CryoCath


CryoCath - - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.

SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. CryoCath announces 2007 fourth quarter and fiscal year end financial results
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
7. CryoCath Provides Update on Patent Infringement Lawsuit
8. CryoCath Announces Fiscal 2008 First Quarter Results
9. CryoCath Technologies notice of annual meeting
10. CryoCath Appoints New Chief Financial Officer
11. CryoCath Introduces Arctic Front in Australia
Post Your Comments:
(Date:11/26/2015)... ... 26, 2015 , ... Patients at Serenity Point Recovery, a ... on Thanksgiving Day to share the things that they are most grateful for ... YouTube channel, patients displayed what they wrote on index cards, describing the things ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... November 26, 2015 , ... The Catalent Applied Drug ... need to integrate dose form selection in early phase drug development. The first ... supporting and bringing together the UK’s emerging life sciences companies, corporate partners, and ...
(Date:11/26/2015)... ... ... PRMA Plastic Surgery is updating their record books yet again with an ... breast reconstruction surgery! , “What an accomplishment for the PRMA team, says Dr. ... an honor to have served all of these women.” , PRMA is one of ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... retro-fused, self-animating trailer titles with ProTrailer: Vintage. This newly styled ProTrailer pack comes ... titles work with any font, giving users limitless opportunities to stylize and create ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
(Date:11/26/2015)... , November 26, 2015 ... the addition of the  "2016 Future ... European Cell Surface Marker Testing Market: ...  report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/25/2015)... -- The American Academy of Pediatrics (AAP), American Congress ... of Dimes cheered today,s signature into law of ... 2015 (S.799), which takes much-needed strides to ... drugs, such as opioids, and to improve their ... have worked together leading advocacy efforts for its ...
Breaking Medicine Technology: